Evidence mapPaperPMID 42250074Full record

ArticleAdvances in therapy2026

Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast.

Megha Poddar, Joe Nadglowski

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Megha PoddarMedical Weight Management Centre of Canada, Hamilton, ON, Canada. megha.poddar@medportal.ca.ORCID http://orcid.org/0000-0002-3329-5621
Joe NadglowskiPatient Author, Obesity Action Coalition, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a chronic, progressive disease defined by excess adiposity that can negatively affect a person's health. Approximately one billion people are living with obesity globally, though this estimate is shaped by the ongoing evolution in how the condition is measured and diagnosed. Although obesity is traditionally diagnosed by body mass index (BMI), it does not adequately assess body fat distribution, particularly visceral fat, which is specifically linked to an increased risk of poor metabolic health and cardiovascular disease. Other anthropometric measures such as waist circumference and waist-to-height ratio assess an indirect measure of visceral adiposity and are better predictors of cardiovascular risk than BMI alone. Obesity can increase the risk of developing type 2 diabetes, lipid dysfunction, and metabolic dysfunction-associated steatotic liver disease (MASLD), a condition in which the liver stores too much fat because the body's metabolism is not working properly. Around 75% of people with obesity have MASLD, with 12% to 40% progressing to metabolic dysfunction-associated steatohepatitis (MASH; the advanced form of MASLD) within 8-13 years. MASH and MASLD are largely underdiagnosed because someone affected by these conditions does not show symptoms. In this podcast, a patient and doctor specialising in obesity medicine share their perspective on the experience and best practice relating to the diagnosis of obesity, the need for screening of obesity complications, and the importance of the assessment and management of liver health as part of a holistic delivery of obesity care.Podcast available for this article. Podcast (MP4 156963 kb).

Indexed as

Liver healthMASHMASLDMetabolic syndromeObesityPrimary care

Identifiers

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.